American Academy of Addiction Psychiatry

Buprenorphine and Office-based Treatment of Opioid Dependence (Live 8 Hour CME Course)

The goal of this program is to acquire the knowledge and skills needed to provide optimal care to opioid dependent patients

Wednesday, December 2, 2009
7:00 am – 5:30 pm

Hyatt Regency Century Plaza
2025 Avenue of the Stars
Los Angeles, California 90067

Live Training Registration Fees

• Students, Residents and Fellows: FREE (Live Training ONLY)
  
• Non-Physicians/Related Health Professionals: $75
• AAAP Members: $100
• Non-Member Physicians: $150

Students, Residents and Fellows interested in attending for free: Registration cannot be completed online for this category.  Please fill out the PDF Registration Form (above) and mail,  fax to (401) 272-0922, or email to buptraining@aaap.org. 

Program Overview

• Federal Center for Substance Abuse Treatment (CSAT) endorses this national training initiative program.
• Qualified Physicians may dispense or prescribe specifically approved Schedule lll, IV and V narcotic medications for treatment of opioid addiction in office-based settings as part of The Drug Abuse Treatment Act (DATA) 2000.
• Physicians qualify after completion of not less than eight (8) hours of approved training.
• This course satisfies the DATA 2000 eight hour training requirement.
• Certificates will be provided to each physician who completes the training confirming the eight hours of training.
• Certificates may be mailed to the Secretary of Health and Human Services along with a Request for Waiver of the special registration requirements defined in the Controlled Substances Act.
• One-on-one mentoring via phone, email or site visit is available through the assistance provided via the Physician Clinical Support System (PCSS), www.pcssmentor.org.

Who Should Attend

This program is recommended for physicians with experience and/or interest in treating opioid dependence. It is also recommended for primary care, psychiatric, HIV, pain and addiction medicine physicians.  For additional information, please visit:

www.samhsa.gov

www.buprenorphine.samhsa.gov

Buprenorphine Training Learning Objectives

At the conclusion of this meeting participants should be able to:

1. Identify the clinically-relevant pharmacological characteristics of buprenorphine
2. Identify and incorporate specific resources to establish office-based treatment with buprenorphine for patients with opioid dependence
3. Describe and contrast the functions of full agonists, partial agonists and antagonists
4. Apply special treatment considerations with adolescent opioid-dependent patients and list factors to consider in evaluating a pregnant opioid-dependent woman
5. Describe symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder

Topics and Goals

Topic: Overview of opioid dependence
Goal: Understand the rationale and need for opioid pharmacotherapy in the treatment of opioid dependence

Topic: Clinical use of buprenorphine and buprenorphine/naloxone, including induction maintenance, and supervised withdrawal, patient assessment and selection, and the efficacy and safety of buprenorphine/naloxone
Goal: Understand induction and maintenance protocols to allow you to help patients with an effective and safe medication

Topic: Legislative changes allowing office-based treatment of opioid dependence, including the Drug addiction Treatment Act of 2000
Goal: Understand specific information on the legislative and regulatory history of office-based opioid pharmacotherapy.

Topic: General opioid pharmacology and pharmacology of buprenorphine and buprenorphine/naloxone
Goal: Understand the pharmacological characteristics of opioids

Topic: Medical and psychiatric conditions in opioid dependent patients
Goal: Understand the current issues related to the medical and psychiatric conditions associated with opioid dependence (HIV/AIDS, Hepatitis C, depression and anxiety)

Topic: Special treatment populations
Goal: Understand the management of pain in patients with addictive disorders, and the management of adolescents and pregnant women with opioid dependence

Topic: Office procedures including confidentiality and record keeping
Goal: Gain the information, tools and contacts to set up office-based treatment with buprenorphine.

Schedule

7:30 AM – 8:00 AM       Registration and Mandatory Sign-in
8:00 AM – 5:30 PM       Program Including Lunch 
5:30 PM                        Mandatory Sign-Out

PLEASE BRING THE FOLLOWING TO THE MEETING:

• DEA Number
• State Medical License Number
• Photo ID

Please note that the American Academy of Addiction psychiatry cannot issue certificates of attendance or confirm training for those who arrive late or depart before the completion of the course

CME Credits

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the medical university of South Carolina and the American Academy of Addiction Psychiatry. The Medical university of South Carolina is accredited by theACCME to provide continuing medical education credit for physicians.

The Medical University of South Carolina designates this educational activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Program Faculty